The mutations that cause cancer cells to grow also confer specific vulnerabilities that normal cells lack. These cancer-specific dependencies are compelling therapeutic targets. The problem is that, for the overwhelming majority of cancers, we do not fully understand relationships between the genetic features of cancer and cancer dependencies. A “cancer dependency map” (for instance, models of all genotypes tested for genetic and small-molecule dependencies) is needed, and the work of the Broad’s Cancer Program is laying the foundation for an international effort to develop such a resource for the community.
To do this, Broad scientists are deploying genetic and small molecule perturbation technologies to triangulate relationships between genomic features and “Achilles’ heels” across a wide-array of cancer types. In collaboration with the Genetic Perturbation Platform, hundreds of genome-wide vulnerability screens have been completed, together with advanced computational algorithms for data analysis. In addition, by working with the Center for the Science of Therapeutics, we have demonstrated the feasibility of new approaches for pinpointing small molecule sensitivities at large-scale. Finally, through efforts such as the Cancer Cell Line Encyclopedia and Cancer Cell Line Factory, we are invested in characterizing, creating, and sharing new cancer cell models as a community effort to accelerate molecular and therapeutic discovery.
- Cancer Dependency Map
- Cancer Cell Line Factory
- Cancer Data Science Group
- Cancer Therapeutics Response Portal
- The Slim Initiative for Genomic Medicine
Results and data from our many projects can be accessed via Broad Data, Software and Tools.